- About
- Organization
- Organization Overview
- Dean’s Office
- Department of Bioengineering and Therapeutic Sciences
- Department of Clinical Pharmacy
- Department of Pharmaceutical Chemistry
- Quantitative Biosciences Institute
- Org Chart
- Research
- Education
- Patient Care
- People
- News
- Events
Scangos named CEO of Biogen Idec
By UCSF School of Pharmacy Editorial Staff / Tue Jul 13, 2010
© 2001 - David Powers
George Scangos, PhD
George Scangos, PhD, a member of the UCSF School of Pharmacy Board of Advisors, has been appointed chief executive officer (CEO) of the global biotechnology company Biogen Idec, which is headquartered in Cambridge, Massachusetts, and Zug, Switzerland. The appointment is effective July 15, 2010. Scangos brings to the company more than 25 years of experience in the biotechnology and pharmaceutical industries. He has served, since 1996, as president and CEO of the South San Francisco-based biotechnology company Exelixis, Inc. after leadership roles at Bayer Corporation. Scangos earned his PhD in microbiology from the University of Massachusetts.
Press release
[Biogen Idec Names George Scangos Chief Executive Officer][link defunct as of July 13, 2013]
Conference call and interview session
[Biogen Idec Inc. Names George Scangos Chief Executive Officer (requires registration)][link defunct as of September 24, 2010]
Tags
Topics:
Category:
Sites:
School of Pharmacy, PharmD Degree Program, Dean's Office
About the School: The UCSF School of Pharmacy aims to solve the most pressing health care problems and strives to ensure that each patient receives the safest, most effective treatments. Our discoveries seed the development of novel therapies, and our researchers consistently lead the nation in NIH funding. The School’s doctor of pharmacy (PharmD) degree program, with its unique emphasis on scientific thinking, prepares students to be critical thinkers and leaders in their field.
Related news
- New associate deans focus on global affairs and industry partnerships
- Inaba named first fellow of Haight Ashbury Free Clinics
- UCSF technology used to trigger cell death becomes basis of company’s cancer therapy research and development
- UCSF welcomes Chancellor Desmond-Hellmann
- Wells receives the Bristol-Myers Squibb Smissman Award
Recent news
Share your news
Faculty and staff: We want to hear about the work that you are engaged in, such as honors and awards received, publications, and events featuring you.